U.S. Markets close in 3 hrs 18 mins

Targacept completes recruitment for Phase 2b study of TC-1734

Targacept announced that it has completed recruitment of patients in the Phase 2b study of TC-1734 as a treatment for mild to moderate Alzheimer's disease. Targacept expects to report top-line results from the study in mid-2014. TC-1734 is a modulator of the alpha4beta2 neuronal nicotinic receptor subtype.